



3rd Year General Meeting of 3D-NET  
Nottingham, 6 and 7<sup>th</sup> of September 2016

AGENDA

Tuesday, 6<sup>th</sup> September

**7:00 pm.** Invited dinner guests at The Lace Market

Wednesday, 7<sup>th</sup> September

**8:30 am to 12:30 pm.** This session will be moderated by Prof. Alan Stitt (Queen University of Belfast) and Prof. David Heal (RenaSci) with the aim to advise on how to progress forward.

**8:30 am**

- Opening of 3D-NET 3<sup>rd</sup> Year General Meeting (*Breandan Kennedy, Project Coordinator*)

**8:45 am**

- **Progress and outlook of WP4:** 3D-NET Project Management & Dissemination (Yolanda Alvarez, Project Manager) ( 10 minutes overview by WP leader and 20 minutes discussion)

**9:15 am**

- **Progress and outlook of WP1:** Discovery Of Small Molecule Drugs With Novel Anti-Angiogenic Efficacy In The Eye (Breandan Kennedy, Work-Package Leader) ( 10 minutes overview by WP leader and 20 minutes discussion)

**9:45 am**

- **Progress and outlook of WP2:** Discovery & Development Of Small Molecule Drugs That Reduce Ocular Inflammation Or Retinal Vasculature Permeability (Robert Haigh, Work-Package Leader) ( 10 minutes overview by WP leader and 20 minutes discussion)

**10:15 am**

- **Progress and outlook of WP3:** Development Of Small Molecule Compounds With “Cell Protective” Activity In The Eye (Yolanda Diebold, Work-Package Leader) ( 10 minutes overview by WP leader and 20 minutes discussion)

**10:45 am**

- **Open discussion/future collaboration Choice of compounds to move into in vivo model** (20 mins)

**11:05 am** Coffee Break (15 minutes)

**Internal 3D-NET associates scientific talks**

**11:20 am**

- Dr. Alison Reynolds (UCD) “**Structure-Activity Relationship of a novel family of cysteinyl leukotriene receptor antagonists with anti-angiogenic activity**”

**11:30 am**

- Dr. Javier Calles (IOBA) “**3D-NET - My experience as MSC fellow**”

**11:40 am**

- Dr. Heika Silveira (KalVista) **“A tale of two cell lines: Biological effect of plasma kallikrein inhibitors, PI3K inhibitors and glucosteroids lead compounds”**

**11:50 am**

- Dr. Jorge Lopez (Gadea) **“Industrial process in synthesis of chemical compounds”**

**12:00 noon**

- Dr. Orla Galvin (RenaSci) **“Retinal Vascular Permeability: Back to the future”**

**12:10 pm**

- Dr. Pilar Ventosa (Gadea) **“Escape Flatland: From Amino Acids to Nature-Inspired Molecular Scaffolds”**

12:30 – 1:00 pm Lunch break

**1.00pm Introduction by Dr. Glenn Crocker (CEO BioCity)**

**1:00-4:30 pm. Ophthalmic Drug Innovation, Regulation and Strategies to Reach the Clinical Market**

Open Scientific Presentations chaired by Sharon Cheetham and Sally Hampton

**1:15 pm**

- Prof. Alan Stitt (Queen University of Belfast) **“Preventing neurovascular degeneration during diabetic retinopathy”**

**1:50 pm**

- Dr. Michael Stocks (University of Nottingham) **“Physicochemical properties to aid drug discovery”**

**2:25 pm** Coffee Break (15 minutes)

**2:40 pm**

- Rachel Morten (KalVista Pharmaceuticals) **“Regulatory Affairs and Early Development - Adding Value”**

**3:15 pm**

- Prof. David Bates (University of Nottingham) **“Development of novel topical therapeutics for vascular retinopathies”**

**4:30. pm** Drinks reception on site

**6:00 pm/7:00 pm** Yamas Restaurant